BeyondSpring Inc. reported a net loss from discontinued operations of $2.2 million for the nine months ended September 2025, compared to $5.0 million for the same period in 2024. The company reclassified SEED Therapeutics' financial results as discontinued operations after entering definitive agreements in January 2025 to sell the majority of its Series A-1 Preferred Shares in SEED. BeyondSpring currently owns about 38% of SEED, with ownership expected to decrease to approximately 14% following completion of future sale transactions. Key business developments included SEED's completion of a $30 million Series A-3 financing, FDA and China NMPA clearance of its IND application for the lead RBM39 degrader program, and SEED being named a finalist for the 2025 Prix Galien USA "Best Start-Up" Award. Additionally, BeyondSpring presented clinical results showing an 85% disease control rate in metastatic NSCLC patients for its dendritic cell maturation agent, Plinabulin, in combination with docetaxel and Keytruda.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007217), on November 12, 2025, and is solely responsible for the information contained therein.
Comments